Answers are grounded in this paper and cite their sources.
Routine laboratory panels drawn during cancer treatment constitute longitudinal physiological recordings of organ function, yet their temporal structure is discarded by single-timepoint prognostic tools. A transformer trained on 2,777,595 laboratory measurements from 3905 patients with multiple myeloma or ovarian cancer predicted which of 162 treatment-associated complications would be newly recorded within two years, spanning eight clinical categories, achieving 1.5- to 6.1-fold enrichment above prevalence. Across individual endpoints it exceeded non-sequential baselines, including engineered-trajectory models, by +0.024 to +0.070 in mean AUROC. Predictions generalised across both cancers, divergence concentrating in disease-specific complications, and biomarker masking recovered signatures consistent with established pathophysiology. External validation on MIMIC-IV and MMRF CoMMpass showed transferability, strongest for renal and metabolic endpoints, attenuated for infection endpoints. On CoMMpass it added prognostic value to ISS staging. Routine oncological laboratory data carry complication-specific physiological signal months before a complication is recorded, and require no testing beyond standard oncological care.
No takes yet. Share an insight, caveat, or question.
Lübberstedt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: